Locations:
Search IconSearch
April 17, 2019/Neurosciences/Research

Prescribing Limits Drive Down Opioid Exposure After Spine Surgery Without Harming Outcomes

Cleveland Clinic study assesses effects of state-level reforms

19-NEU-217-opioids-650x450pxl

Discharge prescribing of opioids after decompressive lumbar spine surgery decreased significantly without any harm detected in global health outcomes among patients at Cleveland Clinic in the year following implementation of state-level opioid prescribing reform. So finds a retrospective review presented this week at the 2019 annual scientific meeting of the American Association of Neurological Surgeons.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Our study clearly showed two things occurred as a result of new state restrictions on opioid prescribing,” says Michael Steinmetz, MD, Chair of Cleveland Clinic’s Department of Neurosurgery and senior author of the study. “First, prescribing behavior on the part of physicians changed. Second, patients were no worse for it.”

Legislative backdrop

On Aug. 31, 2017, the state of Ohio implemented new rules for prescribing opioids to treat acute pain. The rules include a limit on prescriptions to a maximum of seven days for adults and a requirement that the total morphine equivalent dose (MED) of a prescription may not exceed an average of 30 MED per day.

This posed a dramatic change to standard practice: Previously, surgeons routinely prescribed at least a two-week course of opioids at discharge, and it was not unusual to prescribe 90 days of medications to cover the expected postoperative recovery period.

“Despite widespread adoption of similar restrictions by states across the nation, little research has been done on whether such restrictions have made a difference in prescribing practices or patient outcomes,” Dr. Steinmetz notes.

Study design and findings

The study evaluated 1,098 patients who underwent a one- or two-level lumbar laminectomy at Cleveland Clinic during either the 12 months preceding the state-mandated change or the 12 months after.

The researchers found that patients in the year after reform received, on average, a MED total during the 90 days following discharge that was 174 MED lower (95% CI: –261 to –91) than the average for patients in the year prior to reform. No differences were found in the number of opioid prescriptions written, so the decline can be attributed to shorter prescription courses.

Advertisement

The patients also were evaluated postoperatively with the PROMIS-Global Health instrument, a patient-reported assessment of general physical, mental and social health. No difference in scores was found between the pre-reform and post-reform patients.

Implications

Dr. Steinmetz says this is the first study he’s aware of that evaluated changes in opioid prescribing and health outcomes from a hospital database following state-level restrictions on opioid prescribing.

He notes that it would be interesting to see if the reforms also led to reductions in overdose calls or deaths from opioids — although finding that out would require analyzing statewide data.

“This study suggests that state-level reforms placing reasonable limits on opioid prescriptions for acute pain may reduce patients’ opioid exposure without compromising patient-reported outcomes after spine surgery,” he says.

He adds that the implications go beyond the effects on individual patients, noting that patients may limit their use of pain medications and leave the remaining pills in their medicine cabinet, where they can be stolen by friends, relatives or even burglars — for their own use or for sale on the street.

“People just don’t need that much pain medication, even following surgery,” Dr. Steinmetz concludes. “This and similar reforms in other states appear to be excellent public health measures with no discernable downside.”

Advertisement

Related Articles

illustration of brain plus chemical diagram of tavapadon
April 11, 2025/Neurosciences/Research
TEMPO: Tavapadon Shows Promise as Both First and Adjunct Therapy in Parkinson’s

Dopamine agonist performs in patients with early stage and advanced disease

hand of a person doing a crossword puzzle
March 13, 2025/Neurosciences/Research
Novel Tool Assesses Dynamic Neurocognitive Adaptation Across a Lifetime

Validated scale provides a method for understanding how lifestyle may protect against Alzheimer's

brain illustration with a focused inset section labeled "LCN"
February 25, 2025/Neurosciences/Research
Deep Brain Stimulation for Brain Injury Rehab: Do Benefits Continue After Neurostimulation Stops?

Promising preclinical research indicates functional motor recovery is durable

woman in red shirt standing beside a sign for clinical study recruitment
February 20, 2025/Neurosciences/Research
The Cleveland Clinic Brain Study at 3 Years: Initial Insights, Surprises and Next Steps

A principal investigator of the landmark longitudinal study shares interesting observations to date

Medical illustration of brain
January 6, 2025/Neurosciences/Research
Department of Defense Awards $3.4 Million to Advance a Tool for Assessing Return-to-Duty Readiness After Brain Injury

Cleveland Clinic researchers collaborate with Microsoft to create a product ready for the field

Illustration of a brain
November 6, 2024/Neurosciences/Research
Genomic Analysis Finds Connections Between Transposable Elements and Alzheimer's Disease

Understanding TE involvement is a key to developing new treatments

Man on an exercise bicycle
October 29, 2024/Neurosciences/Research
New Parkinson’s Trial Focuses on Interplay Between Exercise and Genetics

Study aims to inform an enhanced approach to exercise as medicine

researcher in dark laboratory
September 12, 2024/Neurosciences/Research
Preclinical Imaging Research Aims to Help Refine Deep Brain Stimulation for Stroke Recovery

$3.2 million grant will fund use of calcium-based imaging to record neuronal activity in ischemia model

Ad